The importance of robust genomic testing for patients

• June 25, 2026

Targeting the E2F6-TOP2A-DKK1 axis: a novel therapeutic strategy for EMT-driven hepatocellular carcinoma progression

• by Mindan Xing, Yi Lu, Yan Guo, Yantao Jiang, Hengqi Liu, Junjie Yu, Luyao Tong, Zhongyu Wang, Chao Li, Xing Chen, Wei Luo

• July 2, 2026

ASCO26: Julia Rotow, MD, Silevertinib in Lung Cancer

Dana-Farber Cancer Institute's Dr. Julia Rotow reported on a study looking at silevertinib, with data showing it may offer a new first-line option for hard-to-treat EGFR non-small cell lung cancer variants, with encouraging brain activity and manageable side effects.

• July 1, 2026

• 1 min

Predicting overall survival in synchronous metastatic nasopharyngeal carcinoma using a stacking ensemble machine learning model: a multicenter retrospective study

• by Canwen Che, Shanyue Lin, Jie Ma, Haibo Liu, Wentao Liu, Zhanhong Tan, Xin Chen, Xiaoyi Zeng, Qiwen Duan, Guanxun Cheng

• July 1, 2026